Genmab — Februar 2018
-
-
@Den Fattige: Du kan læse lidt om forventet kursuvikling efter et "Gaps Away" her: http://www.dstockmarket.com/breakaway-gaps.html
-
Om det er interessant, ved jeg ikke. Men mig bekendt er dette det eneste studie. Et ISS på MD Anderson https://www.clinicaltrials.gov/ct2/show/NCT03177460?term=daratumumab+prostate&rank=1
-
De har jo så også det andet studie i prostata som er aflyst. Nogen som kender begrundelsen. ?? https://www.clinicaltrials.gov/ct2/show?term=daratumumab+prostate&rank=2
-
Noget kunne tyde på, at cd38 spiller en rolle som biomarkør for aggressiv prostata cancer. Men det er vel ikke det samme, som at det kan bruges behandlingsmæssigt? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814231/
-
-
I had thought about this from a different perspective; given that JNJ is rather succesfull in prostate cancer already ( with Zytiga and recently approved apalutamide) i did not expect their main focus to be there. (This was their oncology presentation from last years R&D day http://files.shareholder.com/downloads/JNJ/5911192644x0x943361/95AFD3A4-424F-478E-9914-6CBAF56D2D06/Peter_Lebowitz_Slides.pdf
-
Legolas er skrap til det med at gætte lukkerkurser.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind